CJC-1295 NO DAC, also known as Modified GRF 1-29, is a synthetic peptide analog of growth hormone-releasing hormone (GHRH) designed for laboratory and analytical research.
Unlike CJC-1295 with DAC, CJC-1295 NO DAC does not contain the Drug Affinity Complex (DAC) modification. This specification sheet provides general product information, quality documentation details, storage information, and research-use information for CJC-1295 NO DAC supplied by 52ym.
Product Information
| Item | Specification |
|---|
| Product Name | CJC-1295 NO DAC |
| Common Name | Modified GRF 1-29 |
| Product Type | Research Peptide |
| Application | Laboratory Research Use |
| Appearance | White to off-white lyophilized powder |
| Storage Condition | Store according to product label instructions |
| Purity | Refer to batch-specific product documentation |
| Usage | Research purposes only |
Technical Information
Technical Information
Product Name:
CJC-1295 NO DAC
Common Name:
Modified GRF 1-29
Synonym Names:
CJC-1295 without DAC
CJC-1295 NO DAC
Modified GRF (1-29)
Mod GRF 1-29
Research Area:
Peptide research
GHRH research
Cell signaling studies
Biochemical research
Analytical research
Quality Documentation
Quality Documentation
Available documentation may include:
- Product Specification Sheet
- Certificate of Analysis (COA)
- HPLC analytical documentation
- Mass spectrometry (MS) documentation
- Batch-specific quality information
Documentation availability may vary by batch. Please contact 52ym for current product documentation.
Research Use Statement
Research Use Statement
CJC-1295 NO DAC supplied by 52ym is intended strictly for laboratory research, analytical, and scientific research purposes.
This product is not intended for human consumption, clinical diagnosis, therapeutic use, or veterinary use.
Request Product Information
CJC-1295 NO DAC Product Information
For product specifications, batch documentation, availability, and quotation requests, please visit the CJC-1295 NO DAC product page.
View CJC-1295 NO DAC Product & Request a Quote
Leave a Reply